title: Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors.
authors.affiliation: Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark.
authors.forename: Nynne
authors.initials: N
authors.lastname: Nyboe Andersen
authors.affiliation: Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark.
authors.forename: Björn
authors.initials: B
authors.lastname: Pasternak
authors.affiliation: Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark.
authors.forename: Mikael
authors.initials: M
authors.lastname: Andersson
authors.affiliation: Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark.
authors.forename: Nete Munk
authors.initials: NM
authors.lastname: Nielsen
authors.affiliation: Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark.
authors.forename: Tine
authors.initials: T
authors.lastname: Jess
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003711:Demyelinating Diseases / Q000453:epidemiology* / Q000209:etiology; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha